Latest Conference Articles

December 11th 2021, 7:51pm

ASH Annual Meeting and Exposition

Frontline fixed-duration treatment with ibrutinib plus venetoclax led to deeper and prolonged rates of undetectable minimal residual disease in the bone marrow and peripheral blood, leading to fewer relapses in the first year post-treatment vs chlorambucil plus obinutuzumab in elderly and unfit patients with chronic lymphocytic leukemia.

December 11th 2021, 7:44pm

ASH Annual Meeting and Exposition

The minimal residual disease–guided combination of ibrutinib plus venetoclax was found to be a feasible treatment regimen for patients with relapsed/refractory chronic lymphocytic leukemia.

December 11th 2021, 7:40pm

ASH Annual Meeting and Exposition

Orca-T significantly improved graft-vs-host disease–free relapse-free survival and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved overall survival vs standard of care in patients with serious hematologic malignancies

December 11th 2021, 7:10pm

ASH Annual Meeting and Exposition

Daratumumab, lenalidomide, and dexamethasone demonstrated an overall survival advantage in the first-line setting compared with the same agents in the second-line setting in patients with transplant-ineligible multiple myeloma.

December 11th 2021, 6:32pm

ASH Annual Meeting and Exposition

Fixed-duration treatment with the bispecific antibody mosunetuzumab induced deep and durable responses with favorable tolerability in heavily pretreated patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the ongoing phase 1/2b GO29781 trial.

December 11th 2021, 6:22pm

ASH Annual Meeting and Exposition

The combination of daratumumab plus ixazomib, without dexamethasone, was found to have a favorable safety profile in very elderly frail patients with relapsed or refractory multiple myeloma and high cytogenetic risk.

December 11th 2021, 6:16pm

ASH Annual Meeting and Exposition

Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.

December 11th 2021, 5:56pm

ASH Annual Meeting and Exposition

The combination of ixazomib, daratumumab, and low-dose dexamethasone elicited an objective response rate of 71% in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

December 10th 2021, 11:03pm

San Antonio Breast Cancer Symposium

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.

December 10th 2021, 9:09pm

San Antonio Breast Cancer Symposium

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

December 10th 2021, 8:53pm

San Antonio Breast Cancer Symposium

Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.

December 10th 2021, 8:36pm

San Antonio Breast Cancer Symposium

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.

December 10th 2021, 7:22pm

San Antonio Breast Cancer Symposium

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

December 10th 2021, 7:20pm

San Antonio Breast Cancer Symposium

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

December 10th 2021, 6:22pm

San Antonio Breast Cancer Symposium

Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.

December 9th 2021, 10:17pm

ASH Annual Meeting and Exposition

Second-line lisocabtagene maraleucel demonstrated a favorable improvement in most patient-reported outcome domains compared with standard of care in patients with relapsed or refractory large B-cell lymphoma, and health-related quality of life was found to either be improved or maintained following treatment with the CAR T-cell therapy.

December 9th 2021, 9:45pm

San Antonio Breast Cancer Symposium

Physicians treating patients with early-stage triple-negative breast cancer should employ circulating tumor DNA testing early and often, according to results from the phase 2 cTRAK TN trial.

December 9th 2021, 9:20pm

San Antonio Breast Cancer Symposium

Trastuzumab deruxtecan led to prolonged progression-free survival and higher responses vs trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer across all patients subgroups, including those with and without baseline brain metastases.

December 9th 2021, 9:04pm

San Antonio Breast Cancer Symposium

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

December 9th 2021, 9:01pm

San Antonio Breast Cancer Symposium

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.